Trial Profile
A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Acronyms ADAPT
- 11 Oct 2023 Status changed from not yet recruiting to recruiting.
- 05 Jul 2023 Planned initiation date changed from 1 Jun 2023 to 1 Aug 2023.
- 07 Jun 2023 Planned initiation date changed from 1 Apr 2023 to 1 Jun 2023.